Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03456063 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030)

StatusCompleted
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

The 50 most recent of 84 record versions are accounted for below. See every version on ClinicalTrials.gov ↗

  1. Results posted: Oct 9, 2026 Primary endpoints: 1 to 2 · Study sites: 122 to 117 · Eligibility criteria expanded, about 20 words · 1 more Show 4 more changesShow less
    • Primary endpoints: 1 to 2
    • Study sites: 122 to 117
    • Eligibility criteria expanded, about 20 words
    • Secondary endpoints: 19 to 32
  2. Trial status: Active, Not Recruiting to Completed Study sites: 119 to 122v83 Show 1 more changeShow less
    • Study sites: 119 to 122
  3. Study sites: 117 to 119v82
  4. Study sites: 116 to 117 Primary completion date: Dec 31, 2025 to Oct 1, 2025v81 Show 1 more changeShow less
    • Primary completion date: Dec 31, 2025 to Oct 1, 2025
  5. Study sites: 120 to 116v80
Show 45 earlier versionsHide 45 earlier versions
  1. Study sites: 127 to 120v79
  2. Primary and study completion dates: Jan 19, 2025 to Dec 31, 2025 Site details revised at 1 of 127 sitesv78 Show 1 more changeShow less
    • Site details revised at 1 of 127 sites
  3. Site details revised at 1 of 127 sitesv77
  4. Study sites revised (127)v76 See this version in full on ClinicalTrials.gov ↗
  5. Site details revised at 1 of 127 sitesv75
  6. Site details revised at 1 of 127 sitesv74
  7. Study sites: 128 to 127v73
  8. Re-verified, no change to tracked fieldsv72
  9. Study sites: 129 to 128 Primary and study completion dates: Nov 20, 2024 to Jan 19, 2025v71 Show 1 more changeShow less
    • Primary and study completion dates: Nov 20, 2024 to Jan 19, 2025
  10. Study sites revised (129)v70 See this version in full on ClinicalTrials.gov ↗
  11. Re-verified, no change to tracked fieldsv69
  12. Site details revised at 1 of 129 sitesv68
  13. Enrollment target: 451 to 453 Study sites: 130 to 129v67 Show 1 more changeShow less
    • Study sites: 130 to 129
  14. Enrollment target: 453 to 451 Primary completion date: Apr 20, 2025 to Nov 20, 2024 · Completion date: Apr 20, 2026 to Nov 20, 2024 · Secondary endpoints: details revised at 1 of 19 entriesv66 Show 3 more changesShow less
    • Primary completion date: Apr 20, 2025 to Nov 20, 2024
    • Completion date: Apr 20, 2026 to Nov 20, 2024
    • Secondary endpoints: details revised at 1 of 19 entries
  15. 2 versions Re-verified since Jan 4, 2022, no change to tracked fieldsv64-v65
  16. Study sites: 131 to 130v63
  17. 2 versions Re-verified since Oct 12, 2021, no change to tracked fieldsv61-v62
  18. Study sites: 132 to 131v60
  19. Primary completion date: Jan 20, 2024 to Apr 20, 2025 Trial status: Recruiting to Active, Not Recruiting · Enrollment target: estimated 450 to confirmed 453 · Study sites: 167 to 132 · 2 morev59 Show 5 more changesShow less
    • Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 450 to confirmed 453
    • Study sites: 167 to 132
    • Completion date: Jan 20, 2025 to Apr 20, 2026
    • Secondary endpoints: 15 to 19

    See this version in full on ClinicalTrials.gov ↗

  20. Study sites: 168 to 167v58
  21. Site details revised at 8 of 168 sitesv57
  22. Site details revised at 7 of 168 sitesv56
  23. Site details revised at 13 of 168 sitesv55
  24. Site details revised at 11 of 168 sitesv54
  25. Primary endpoints: 2 to 1 Primary completion date: Dec 20, 2024 to Jan 20, 2024 · Completion date: Dec 20, 2024 to Jan 20, 2025 · Secondary endpoints revised (15) · 1 morev53 Show 4 more changesShow less
    • Primary completion date: Dec 20, 2024 to Jan 20, 2024
    • Completion date: Dec 20, 2024 to Jan 20, 2025
    • Secondary endpoints revised (15)
    • Site details revised at 5 of 168 sites

    See this version in full on ClinicalTrials.gov ↗

  26. Site details revised at 9 of 168 sitesv52
  27. Site details revised at 21 of 168 sitesv51
  28. Primary and study completion dates: Nov 20, 2024 to Dec 20, 2024 Site details revised at 1 of 168 sitesv50 Show 1 more changeShow less
    • Site details revised at 1 of 168 sites
  29. Study sites: 167 to 168v49
  30. Site details revised at 10 of 167 sitesv48
  31. Site details revised at 8 of 167 sitesv47
  32. Site details revised at 5 of 167 sitesv46
  33. Site details revised at 6 of 167 sitesv45
  34. Site details revised at 5 of 167 sitesv44
  35. Study sites: 166 to 167v43
  36. Study sites revised (166)v42 See this version in full on ClinicalTrials.gov ↗
  37. Enrollment target: 374 to 450 Secondary endpoints revised (15) · Site details revised at 13 of 166 sitesv41 Show 2 more changesShow less
    • Secondary endpoints revised (15)
    • Site details revised at 13 of 166 sites

    See this version in full on ClinicalTrials.gov ↗

  38. Site details revised at 12 of 166 sitesv40
  39. Site details revised at 11 of 166 sitesv39
  40. Site details revised at 8 of 166 sitesv38
  41. Study sites: 167 to 166v37
  42. Primary and study completion dates: Mar 30, 2025 to Nov 20, 2024 Study sites revised (167)v36 Show 1 more changeShow less
    • Study sites revised (167)

    See this version in full on ClinicalTrials.gov ↗

  43. Study sites: 166 to 167v35
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a randomized, double-blinded study designed to evaluate the efficacy, safety, pharmacokinetics, and immunogenicity of neoadjuvant treatment with atezolizumab (MPDL3280A) or placebo in combination with platinum-based chemotherapy in participants with resectable Stage II, IIIA, or select IIIB non-small cell lung cancer (NSCLC) followed by open-label adjuvant/postoperative atezolizumab or best supportive care and monitoring.
Trial Details
NCT Number NCT03456063
Lead Sponsor Hoffmann-La Roche
Conditions Non-Small-Cell Lung
Enrollment 453 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov